Document Detail


The epicardium as a candidate for heart regeneration.
MedLine Citation:
PMID:  22185446     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The mammalian heart loses its regenerative capacity during early postnatal stages; consequently, individuals surviving myocardial infarction are at risk of heart failure due to excessive fibrosis and maladaptive remodeling. There is an urgent need, therefore, to develop novel therapies for myocardial and coronary vascular regeneration. The epicardium-derived cells present a tractable resident progenitor source with the potential to stimulate neovasculogenesis and contribute de novo cardiomyocytes. The ability to revive ordinarily dormant epicardium-derived cells lies in the identification of key stimulatory factors, such as Tβ4, and elucidation of the molecular cues used in the embryo to orchestrate cardiovascular development. myocardial infarction injury signaling reactivates the adult epicardium; understanding the timing and magnitude of these signals will enlighten strategies for myocardial repair.
Authors:
Nicola Smart; Paul R Riley
Related Documents :
21138516 - Left and right ventricular systolic long-axis function and diastolic function in patien...
8901716 - Outcome of patients with ectopia cordis and significant intracardiac defects.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Future cardiology     Volume:  8     ISSN:  1744-8298     ISO Abbreviation:  Future Cardiol     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-21     Completed Date:  2012-04-30     Revised Date:  2014-04-17    
Medline Journal Info:
Nlm Unique ID:  101239345     Medline TA:  Future Cardiol     Country:  England    
Other Details:
Languages:  eng     Pagination:  53-69     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coronary Vessels / cytology*,  pathology
Extracellular Matrix
Humans
Myocardial Infarction / pathology,  therapy*
Myocardium / cytology,  pathology
Myocytes, Cardiac / cytology*,  pathology
Pericardium / cytology*,  pathology
Regenerative Medicine
Signal Transduction
Stem Cells
Thymosin
Vascular Endothelial Growth Factor A
Grant Support
ID/Acronym/Agency:
FS/08/004/23625//British Heart Foundation; //British Heart Foundation
Chemical
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A; 61512-21-8/Thymosin; 77591-33-4/thymosin beta(4)
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human spermatagonial stem cells: a novel therapeutic hope for cardiac regeneration and repair?
Next Document:  Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clini...